TD Capital Management’s AstraZeneca AZN Stock Holding History

TD Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.4K	Hold	113	–	–	﹤0.01%	356
2026 Q1	$22.3K	Buy	+113	New	+$21.8K	﹤0.01%	350
2025 Q4	–	Sell	-113	Closed	-$17.3K	–	821
2025 Q3	$17.3K	Hold	113	–	–	﹤0.01%	349
2025 Q2	$15.8K	Buy	113 +55	+95%	+$7.71K	﹤0.01%	352
2025 Q1	$8.5K	Buy	58 +34	+142%	+$4.92K	﹤0.01%	326
2024 Q4	$3.08K	Buy	+24	New	+$3.36K	﹤0.01%	396
2023 Q3	–	Sell	-50	Closed	-$7.16K	–	413
2023 Q2	$7.16K	Hold	50	–	–	﹤0.01%	301
2023 Q1	$6.94K	Buy	+50	New	+$6.73K	﹤0.01%	296

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TD Capital Management's AZN Position: Q2 2026 in Review

TD Capital Management held its AstraZeneca (AZN) position steady in Q2 2026 at 113 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #356.

TD Capital Management first reported a position in AZN in Q1 2023 and has held it in 8 quarters since. The position peaked at $22.3K in Q1 2026. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

TD Capital Management held 113 shares of AstraZeneca worth $21.4K as of Q2 2026.
TD Capital Management left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up ﹤0.01% of TD Capital Management's portfolio in Q2 2026, its #356 holding.
TD Capital Management first reported a position in AstraZeneca in Q1 2023 and has held it in 8 quarters since.
TD Capital Management's AstraZeneca position peaked at $22.3K in Q1 2026.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on TD Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.